Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
Vertex Pharmaceuticals(VRTX) stock is priced at $477.89, giving the company a market capitalization of 121.35B. It carries a P/E multiple of 30.95.
During the trading session on 2026-03-05, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $480.68 and a low of $470.43. At a current price of $477.89, the stock is +1.6% higher than the low and still -0.6% under the high.
Trading volume for Vertex Pharmaceuticals(VRTX) stock has reached 989.13K, versus its average volume of 1.17M.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
VRTX News
If you are wondering whether Vertex Pharmaceuticals is still reasonably priced after its big run in recent years, you are not alone. This article is here to hel...
Key Points CRISPR Therapeutics' gene-editing platform looks fairly promising, but plenty of challenges could sink the stock. Vertex Pharmaceuticals has a robu...
Tuesday, March 3, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports o...
Analyst ratings
75%
of 32 ratingsMore VRTX News
Renewed takeover speculation is circulating around CRISPR Therapeutics (NasdaqGM:CRSP), with fresh rumors pointing to Vertex Pharmaceuticals as a potential acqu...
Vertex Pharmaceuticals (VRTX) is back in focus after reporting fiscal Q4 results that topped earnings and revenue expectations, drawing fresh attention to its l...
Top-Rated Stocks: Vertex Pharmaceuticals Sees Composite Rating Climb To 96 2/16/2026 Vertex Pharmaceuticals saw its IBD SmartSelect Composite Rating rise to 96...
Senior executives at Vertex Pharmaceuticals (NasdaqGS:VRTX), including the SVP & Chief Accounting Officer and the Executive Vice President & Chief Legal Officer...
Vertex Pharmaceuticals (NasdaqGS:VRTX) has expanded beyond cystic fibrosis with recent approvals for Casgevy, a gene-editing therapy for sickle cell disease and...
Vertex Pharmaceuticals Inc. (VRTX) announced an update on their ongoing clinical study. Vertex Study Tracks New Pain Drug in Breastfeeding Women The study, ti...
Key Points Centessa Pharmaceuticals has a promising candidate, but plenty of work remains before it can launch it. Vertex Pharmaceuticals has a rich lineup of...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.